On June 23, Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.
The company's Iohexol injection (100ml: 35g(I)) was proposed to be selected in the centralized procurement.
Iohexol Injection (100ml: 35g(I)) passed the consistency evaluation of generic products’ quality and efficacy in Apr. 2021. In 2020, the sales revenue from Iohexol Injection was RMB220.96 million, accounting for approximately 26.71% of the operation income of the company.
The relevant information is hereby announced as below:
Generic name of the drug
Proposed selected price
Procurement lead time
X-ray contrast agents It can be used for cardiovascular angiography, arteriography, urography, venography, enhanced CT examinations etc.
Note: The abovementioned product’s proposed winning price and information will be subject to the final announcement issued by the Joint Procurement Office. You can have a look at the iohexol package insert here.